Switch theme
Sign up to access all valuation multiples
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
2003
108
LTM Revenue $8.9M
LTM EBITDA -$51.4M
$198M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nanobiotix has a last 12-month revenue (LTM) of $8.9M and a last 12-month EBITDA of -$51.4M.
In the most recent fiscal year, Nanobiotix achieved revenue of -$13.0M and an EBITDA of -$65.5M.
Nanobiotix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nanobiotix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.9M | XXX | -$13.0M | XXX | XXX | XXX |
| Gross Profit | $8.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$51.4M | XXX | -$65.5M | XXX | XXX | XXX |
| EBITDA Margin | -580% | XXX | 502% | XXX | XXX | XXX |
| EBIT | -$57.4M | XXX | -$76.8M | XXX | XXX | XXX |
| EBIT Margin | -648% | XXX | 589% | XXX | XXX | XXX |
| Net Profit | -$56.4M | XXX | -$76.5M | XXX | XXX | XXX |
| Net Margin | -636% | XXX | 587% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nanobiotix's stock price is EUR 4 (or $4).
Nanobiotix has current market cap of EUR 175M (or $196M), and EV of EUR 176M (or $198M).
See Nanobiotix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $198M | $196M | XXX | XXX | XXX | XXX | $-1.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nanobiotix has market cap of $196M and EV of $198M.
Nanobiotix's trades at -15.1x EV/Revenue multiple, and -3.0x EV/EBITDA.
Equity research analysts estimate Nanobiotix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nanobiotix has a P/E ratio of -3.5x.
See valuation multiples for Nanobiotix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $196M | XXX | $196M | XXX | XXX | XXX |
| EV (current) | $198M | XXX | $198M | XXX | XXX | XXX |
| EV/Revenue | 22.3x | XXX | -15.1x | XXX | XXX | XXX |
| EV/EBITDA | -3.8x | XXX | -3.0x | XXX | XXX | XXX |
| EV/EBIT | -3.4x | XXX | -2.6x | XXX | XXX | XXX |
| EV/Gross Profit | 22.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.5x | XXX | -2.6x | XXX | XXX | XXX |
| EV/FCF | -4.9x | XXX | -8.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNanobiotix's last 12 month revenue growth is 345%
Nanobiotix's revenue per employee in the last FY averaged -$0.1M, while opex per employee averaged $0.6M for the same period.
Nanobiotix's rule of 40 is 245% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nanobiotix's rule of X is 283% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nanobiotix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 345% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -580% | XXX | 502% | XXX | XXX | XXX |
| EBITDA Growth | -68% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 245% | XXX | 848% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 283% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | -$0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | -349% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | -489% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanobiotix acquired XXX companies to date.
Last acquisition by Nanobiotix was XXXXXXXX, XXXXX XXXXX XXXXXX . Nanobiotix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nanobiotix founded? | Nanobiotix was founded in 2003. |
| Where is Nanobiotix headquartered? | Nanobiotix is headquartered in France. |
| How many employees does Nanobiotix have? | As of today, Nanobiotix has 108 employees. |
| Who is the CEO of Nanobiotix? | Nanobiotix's CEO is Dr. Laurent Levy, PhD. |
| Is Nanobiotix publicy listed? | Yes, Nanobiotix is a public company listed on PAR. |
| What is the stock symbol of Nanobiotix? | Nanobiotix trades under NANO ticker. |
| When did Nanobiotix go public? | Nanobiotix went public in 2012. |
| Who are competitors of Nanobiotix? | Similar companies to Nanobiotix include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nanobiotix? | Nanobiotix's current market cap is $196M |
| What is the current revenue of Nanobiotix? | Nanobiotix's last 12 months revenue is $8.9M. |
| What is the current revenue growth of Nanobiotix? | Nanobiotix revenue growth (NTM/LTM) is 345%. |
| What is the current EV/Revenue multiple of Nanobiotix? | Current revenue multiple of Nanobiotix is 22.3x. |
| Is Nanobiotix profitable? | Yes, Nanobiotix is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nanobiotix? | Nanobiotix's last 12 months EBITDA is -$51.4M. |
| What is Nanobiotix's EBITDA margin? | Nanobiotix's last 12 months EBITDA margin is -580%. |
| What is the current EV/EBITDA multiple of Nanobiotix? | Current EBITDA multiple of Nanobiotix is -3.8x. |
| What is the current FCF of Nanobiotix? | Nanobiotix's last 12 months FCF is -$40.0M. |
| What is Nanobiotix's FCF margin? | Nanobiotix's last 12 months FCF margin is -452%. |
| What is the current EV/FCF multiple of Nanobiotix? | Current FCF multiple of Nanobiotix is -4.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
